Accueil・Liste d'Actions・Cytokinetics Inc

Cytokinetics Inc

Fermé

SecteurSoins de santé

76.02 -1.43

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

74.77

Max

77.12

Chiffres clés
By Trading Economics
Revenu	-23M -206M
Ventes	1.6M 19M
BPA	-1.67
Marge bénéficiaire	-1,064.485
Employés	673
EBITDA	11M -169M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+42.36% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2.7B 11B
Ouverture précédente	77.45
Clôture précédente	76.02

Cytokinetics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 août 2026, 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

31 juil. 2026, 20:02 UTC

Event

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

30 juil. 2026, 18:46 UTC

Event

News

Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29 juil. 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28 juil. 2026, 19:06 UTC

News

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

27 juil. 2026, 19:56 UTC

Social Media

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

24 juil. 2026, 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

22 juil. 2026, 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

21 juil. 2026, 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

20 juil. 2026, 19:22 UTC

News

Social Media

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.

Comparaison

Variation de prix

Cytokinetics Inc prévision

Objectif de Prix

By TipRanks

42.36% hausse

Prévisions sur 12 Mois

Moyen 109.8 USD 42.36%

Haut 146 USD

Bas 83 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

Achat

Maintien

Vente

Basé sur 16 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.